Patients with cancer, who’ve had at least one previous treatment and whose tumor tissue shows a specific genetic mutation, could be eligible for one of many clinical trials each testing a novel oral agent.

Investigator:  Bill G Schmidt, MD

Status: Recruiting

Phase: 2

Sponsor: Novartis Pharmaceuticals

Contact: Christine Reed, 541-706-6592 or creed@bmctotalcare.com

Location: Bend, Oregon (Central Oregon)

Click on the links below to see details of the included individual trials at ClinicalTrials.gov:

NCT01981187
NCT02002689
NCT01833169
NCT01831726
NCT01885195
NCT02186821
NCT02187783
NCT02160041

For general inquiries, please contact the BMC Research Department at research@bmctotalcare.com or 877-692-8338.

Back to Clinical Research

image_printPrint

One Response

  1. Eleanort June 29, 2024 at 6:23 am |

    What an enlightening article! It provided a lot of food for thought. Let’s discuss this further. Click on my nickname for more!

Post Comment